James Gilmore III is Insider at BARR PHARMACEUTICALS INC (BRL). They have made 15 open-market trades across 4 companies since 2006, most recently 2019-05-20.
CIK 0001237270
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 15 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| CACI | SELL | 2019-05-20 | 2019-05-21 | $203.18 | $42K | -2.1% | +2.0% | +1.9% |
| CACI | SELL | 2019-03-05 | 2019-03-07 | $181.49 | $49K | +2.7% | +3.2% | +14.5% |
| AAWW | SELL | 2017-03-01 | 2017-03-01 | $58.77 | $447K | -6.5% | -3.7% | -14.8% |
| CACI | SELL | 2011-03-14 | 2011-03-15 | $58.35 | $12K | -5.3% | -2.0% | -2.0% |
| CACI | SELL | 2010-12-01 | 2010-12-02 | $50.99 | $17K | -5.3% | -2.0% | -2.0% |
| CACI | SELL | 2010-09-07 | 2010-09-08 | $42.35 | $14K | -5.3% | -2.0% | -2.0% |
| CACI | SELL | 2010-06-02 | 2010-06-03 | $45.33 | $16K | -5.3% | -2.0% | -2.0% |
| AAWW | SELL · 10b5-1 | 2010-03-25 | 2010-03-26 | $51.40 | $103K | -17.2% | -0.7% | -0.7% |
| CACI | SELL | 2010-03-08 | 2010-03-09 | $51.05 | $16K | -5.3% | -2.0% | -2.0% |
| AAWW | SELL · 10b5-1 | 2010-02-01 | 2010-03-10 | $39.77 | $159K | -17.2% | -0.7% | -0.7% |
| BRL | SELL | 2008-12-16 | 2008-12-18 | $65.18 | $652K | N/A | N/A | N/A |
| BRL | SELL | 2008-12-16 | 2008-12-18 | $65.22 | $417K | N/A | N/A | N/A |
| BRL | SELL | 2008-12-16 | 2008-12-18 | $65.34 | $222K | N/A | N/A | N/A |
| BRL | SELL | 2008-12-08 | 2008-12-09 | $65.66 | $1.2M | N/A | N/A | N/A |
| BRL | SELL | 2008-11-25 | 2008-11-28 | $65.25 | $1.1M | N/A | N/A | N/A |
| BRL | SELL | 2008-11-11 | 2008-11-13 | $64.66 | $3.2M | N/A | N/A | N/A |
| IDT,IDT.C | SELL | 2006-10-18 | 2006-10-20 | $12.76 | $232K | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.